* GoodRx Holdings Inc GDRX.OQ GDRX.O is expected to show
a
rise in quarterly revenue when it reports results on November 7
for the period ending September 30 2024
* The Santa Monica California-based company is expected to
report
a 8.7% increase in revenue to $195.654 million from $179.96
million a year ago, according to the mean estimate from 14
analysts, based on LSEG data.The company's guidance on August 8
2024, for the period ended September 30, was for revenue between
$193.00 million and $197.00 million. (SAL is based on Total
Revenue basis)
* LSEG's mean analyst estimate for GoodRx Holdings Inc is
for
earnings of 9 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for GoodRx
Holdings
Inc is 9.25, above its last closing price of $5.94.
The company's guidance on August 8 2024 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD193 million and
USD63.04 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 0.08 0.09 0.08 Missed -8.4
Mar. 31 0001 0.07 0.08 0.08 Met 6.6
Jan. 1 0001 0.08 0.07 0.08 Beat 18.5
Sep. 30 2023 0.06 0.06 0.06 Met 3.8
Jun. 0.06 0.06 0.07 Beat 15.8
30 2023
Mar. 31 2023 0.06 0.06 0.07 Beat 25.3
Dec. 31 2022 0.05 0.05 0.07 Beat 52
Sep. 30 2022 0.04 0.04 0.07 Beat 72.6
This summary was machine generated November 6 at 14:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)